UCLA Health: Physician-Scientist Receives NCI Grant to Advance Cell-Based Cancer Treatments
December 07, 2024
December 07, 2024
LOS ANGELES, California, Dec. 7 (TNSres) -- The UCLA Health issued the following news release:
Dr. Christopher Seet, an assistant professor of hematology-oncology at the David Geffen School of Medicine at UCLA, has received a $2.9 million R37 MERIT Award from the National Cancer Institute to advance the development of innovative T cell therapies for cancer.
T cell therapies, a form of immunotherapy involving genetically engineered cells to target and destroy cancer cel . . .
Dr. Christopher Seet, an assistant professor of hematology-oncology at the David Geffen School of Medicine at UCLA, has received a $2.9 million R37 MERIT Award from the National Cancer Institute to advance the development of innovative T cell therapies for cancer.
T cell therapies, a form of immunotherapy involving genetically engineered cells to target and destroy cancer cel . . .